Brief: FDA Alerts Health Care Providers, Patients On Increased Risk Of New Blood Cancers With Tazverik Use
11/05/2026 19:36
May 11 (Reuters) - FDA: FDA: ALERTS HEALTH CARE PROVIDERS AND PATIENTS ABOUT INCREASED RISK OF NEW BLOOD CANCERS WITH TAZVERIK (TAZEMETOSTAT) USE FDA - EXPANDED ACCESS PROGRAMS FOR TAZVERIK WILL BE DISCONTINUED AS WELL ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients